# OnCo record paper-adaura-8-year-os-jto-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-adaura-8-year-os-jto-2026" ;
  schema:name "ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer"@en ;
  schema:description "Eight years after surgery, about three in four patients who took osimertinib for three years were still alive, compared with under six in ten on placebo: the longest survival follow-up from any global adjuvant trial in EGFR-mutated lung cancer."@en ;
  schema:url <https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.jtho.2026.104179>, <https://pubmed.ncbi.nlm.nih.gov/42732874/>, <https://clinicaltrials.gov/study/NCT02511106> ;
  schema:sameAs <https://doi.org/10.1016/j.jtho.2026.104179> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Wu YL, Majem M, John T, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/data-maturity/> ;
  onco:trials <https://onco.cc/trials/adaura/> ;
  onco:people <https://onco.cc/people/wu-yi-long/>, <https://onco.cc/people/lu-shun/>, <https://onco.cc/people/roy-herbst/> ;
  onco:journals <https://onco.cc/journals/journal-of-thoracic-oncology/> .